Curaleaf (OTCMKTS:CURLF) is a leading vertically integrated cannabis company focused on providing a comprehensive range of medical and wellness products across multiple markets. Established in 2010 and headquartered in New Jersey, the company has built a robust infrastructure encompassing cultivation, processing, product development and retail operations. Curaleaf operates dozens of dispensaries and cultivation sites throughout North America, supported by state-of-the-art extraction and manufacturing facilities that adhere to rigorous quality and safety standards.
The company’s product portfolio spans a wide array of cannabis offerings, including dried flower, oils, capsules, tinctures, topicals, edibles and vape cartridges. Curaleaf’s brands—such as Select, Curaleaf, and EMMAC in Europe—cater to both medical patients and adult-use consumers, emphasizing consistent potency, purity and innovation. Research and development efforts are directed toward novel delivery systems, balanced cannabinoid profiles and wellness-focused formulations designed to address pain management, stress relief, sleep support and other therapeutic needs.
With operations in more than 20 U.S. states and an expanding footprint in Europe, Curaleaf serves diverse regulatory environments and patient communities. In the United States, the company holds licenses in key markets such as California, Florida, New York and Massachusetts, while its international arm extends into the United Kingdom, Germany, Portugal and Malta. This geographic breadth enables Curaleaf to leverage best practices in cultivation, processing and compliance, driving scalable growth across regulated markets.
Under the leadership of Chief Executive Officer Matt Darin and Chairman Boris Jordan, Curaleaf has pursued strategic acquisitions and partnerships to strengthen its market position and accelerate product innovation. Drawing on a leadership team with deep experience in consumer goods, life sciences and regulated industries, the company remains committed to advancing cannabis research, ensuring patient access and delivering value to stakeholders through operational excellence.
